BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morris JS, Hassan MM, Zohner YE, Wang Z, Xiao L, Rashid A, Haque A, Abdel-Wahab R, Mohamed YI, Ballard KL, Wolff RA, George B, Li L, Allen G, Weylandt M, Li D, Wang W, Raghav K, Yao J, Amin HM, Kaseb AO. HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology 2021;73:2278-92. [PMID: 32931023 DOI: 10.1002/hep.31555] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun L, Guan A, Liu M, Mao Y. Letter to the Editor: Comment on "HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk". Hepatology 2021;73:2613-4. [PMID: 33169424 DOI: 10.1002/hep.31621] [Reference Citation Analysis]
2 Wang Z, Baladandayuthapani V, Kaseb AO, Amin HM, Hassan MM, Wang W, Morris JS. Bayesian Edge Regression in Undirected Graphical Models to Characterize Interpatient Heterogeneity in Cancer. Journal of the American Statistical Association. [DOI: 10.1080/01621459.2021.2000866] [Reference Citation Analysis]
3 Mohamed YI, Lee S, Xiao L, Hassan MM, Qayyum A, Hiatia R, Pestana RC, Haque A, George B, Rashid A, Duda DG, Elghazaly H, Wolff RA, Morris JS, Yao J, Amin HM, Kaseb AO. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget 2021;12:756-66. [PMID: 33889299 DOI: 10.18632/oncotarget.27924] [Reference Citation Analysis]
4 Huo TI, Liu PH, Hsu CY. Letter to the Editor: Using Circulating Biomarkers to Stage HCC: Pitfalls and Limitations. Hepatology 2021;73:2611. [PMID: 33170973 DOI: 10.1002/hep.31618] [Reference Citation Analysis]